Santaris licenses miR-33 from MGH to treat cardiovascular disorders

NewsGuard 100/100 Score
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital (MGH) for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders. Santaris Pharma A/S will utilize its Locked Nucleic Acid (LNA) Drug Platform to develop a LNA-based drug targeting miR-33, an important microRNA that regulates high density lipoprotein (HDL) levels or "good" cholesterol.

Cholesterol is an essential component of all cells and several important hormones, but cholesterol levels that are out of balance or too high overall lead to the formation of atherosclerotic plaques that cause heart attacks or strokes. According to the World Health Organization, cardiovascular diseases are the number one cause of death globally and by 2030, almost 23.6 million people will die from cardiovascular diseases, mainly from heart disease and stroke.

"We are excited to have licensed the intellectual property related to the regulation of miR-33 from Mass General Hospital as it is a promising new target to raise HDL or the 'good' cholesterol in patients who are suffering from cardiovascular diseases," said Soeren Tulstrup, President and CEO of Santaris Pharma A/S. "With our leadership position in microRNA drug development having advanced miravirsen into Phase 2 clinical trials and a keen focus on developing cardiovascular therapies, we are well positioned to expand our cardiovascular disease portfolio for the benefit of patients who are in need of new therapies to better control their cholesterol levels."

Last year, MGH researchers published data in Science identifying tiny segments of RNA, microRNAs, which play an important role in the body's regulation of cholesterol and lipids. Their study found that the miR-33 family of microRNAs suppresses a protein known to be important for generation of HDL and for the removal of cholesterol from peripheral tissues, including cells that form atherosclerotic plaques. Data show that turning off miR-33 raises HDL levels suggesting miR-33 as a novel target in the treatment of cardiovascular and metabolic disorders.

"Current treatments for such cholesterol abnormalities as low circulating HDL levels are only modestly effective, and there is an urgent need for new therapeutic strategies," said Anders Naar, Ph.D., of the MGH Center for Cancer Research, who led the Science study. "Our discovery of miR-33 as a key regulator of HDL has provided a novel therapeutic target for antisense-based technologies to ameliorate cardiometabolic disorders."

The Santaris Pharma A/S LNA Drug Platform is the only RNA technology with both mRNA and microRNA targeted drugs in clinical trials, demonstrating the broad utility of the proprietary platform. In September 2010, Santaris Pharma A/S successfully advanced miravirsen, a lead microRNA drug candidate targeting miR-122, into Phase 2 studies for the treatment of patients infected with the Hepatitis C virus. In addition, Santaris Pharma A/S is advancing two mRNA-targeted drugs, SPC5001 targeting PCSK9 and SPC4955 targeting apoB, for the treatment of high cholesterol into Phase 1 in the first half of 2011.

RNA-targeted drugs are a promising new class of therapeutics that are enabling scientists to develop drugs to work through targets thought to be inaccessible to small molecules and monoclonal antibodies. The LNA Drug Platform utilizing Santaris Pharma A/S proprietary single-stranded LNA chemistry may provide the key to delivering on the promise of RNA-targeted therapies today by overcoming the limitation of earlier antisense and siRNA technologies. The unique combination of small size and high affinity achievable with Santaris Pharma A/S LNA technology allows LNA-based drugs to potently and specifically inhibit RNA targets in different tissues without the need for complex delivery vehicles.


Santaris Pharma A/S


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Beta-blockers show no benefit for heart attack patients with normal heart function